ReviewStenotrophomonas maltophilia: the significance and role as a nosocomial pathogen
Introduction
Stenotrophomonas maltophilia (previously known as Pseudomonas maltophilia or Xanthomonas maltophilia) is a non-fermentative, Gram-negative bacillus, which has assumed an increasingly important role as a nosocomial pathogen in compromised patients.1 Although it was considered previously to have limited pathogenicity, reports indicate that infection with this organism is associated with significant morbidity and mortality particularly in severely compromised patients.2 Treatment of S. maltophilia infections is also complicated by the fact that isolates are inherently resistant to many of the currently available broad-spectrum agents including carbapenems.3 In recent years several trials have elucidated risk factors for S. maltophilia infection, which include neutropenia, the presence of a central venous catheter (CVC), prolonged hospitalization and previous therapy with broad-spectrum antibiotics.4 However, the clinical consequences of infection and the consensus to the most appropriate is not clearly established.
This review will focus on the emerging role and clinical significance of S. maltophilia as a nosocomial pathogen. Also current knowledge of therapeutic considerations important for the management of S. maltophilia infections will be reviewed.
Section snippets
Microbiological background
S. maltophilia is a motile, non-fermentative, oxidase-negative, aerobic Gram-negative bacillus which is widespread in the environment. Originally included in the genus Pseudomonas, it was then transferred to the genus Xanthomonas. Recently it has been reclassified as the single species of the new genus Stenotrophomonas.5
S. maltophilia grows on most bacteriological media, typically producing pigmented (yellow or lavender–green) colonies. The organism can be identified in the clinical laboratory
Epidemiology
S. maltophilia is ubiquitous in the environment with wide geographic distribution. The organism can readily be isolated from water, soil, plants, animal sources and sewage. The wide range of nosocomial sources from which the bacterium has been isolated are summarized in Table I. It is also common in the hospital setting, usually as a commensal, contaminant or part of the patient's endogenous flora.1 Isolation from human faeces was first noted in 1961 by Hugh.7 After that few studies have
Predisposing factors
Studies analysing predisposing factors have elucidated several risk factors associated with S. maltophilia infection, and these are summarized in Table II. Among these, prior exposure to antimicrobial agents has been consistently associated with S. maltophilia infection. Particularly prior therapy with carbapenems, to which the bacterium is inherently resistant, has been cited by several authors. In a study Elting et al.22 found prior therapy with imipenem was 10 times more frequent among cases
Clinical manifestations
S. maltophilia is associated with an expanding spectrum of clinical syndromes; these are summarized in Table III. Bacteraemia and pneumonia are the two most common manifestations and both are associated with high mortality. An increase in the incidence of bacteraemia has been observed, especially during the last two decades.7., 11., 13., 14. Although the portal of the entry was unknown in more than half of the episodes, evidence indicates the importance of intravascular devices for bacteraemia.
Treatment of S. maltophilia infection
One striking characteristic of S. maltophilia is its inherent resistance to many of the currently available broad-spectrum antibiotics. S. maltophilia strains are considered resistant to virtually all classes of beta-lactams including extended-spectrum penicillins, third-generation cephalosporins and carbapenems and to variety of other antibiotics, including aminoglycosides (AGA), with variable susceptibility to fluoroquinolones.6., 7.
Multiple mechanisms are involved in the high-level
Conclusion
Despite the recognition of S. maltophilia as an important nosocomial pathogen, little is known about the epidemiology of this organism in the hospital setting. Also there is no clear consensus as to the most appropriate therapy. Large, controlled studies evaluating the role of antimicrobial combinations in clinical practice and correlating the susceptibility testing results with clinical outcomes are needed.
Recent evidence indicates that the incidence and importance of S. maltophilia infections
References (55)
The emergence of epidemic, multiple antibiotic resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia
J Hosp Infect
(1995)- et al.
Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes
J Infect
(2002) - et al.
Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via water
Am J Med Sci
(2002) - et al.
Molecular epidemiology of Stenotrophomonas maltophilia in a university hospital
J Hosp Infect
(2002) - et al.
Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients
Resp Med
(1996) - et al.
Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis
Chest
(2002) - et al.
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations
Diagn Microbiol Infect Dis
(2001) - et al.
Comparison of various invitro susceptibility methods for testing Stenotrophomonas maltophilia
Diagn Microbiol Infect Dis
(1998) - et al.
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer
Rev Infect Dis
(1990) - et al.
Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital
J Clin Microbiol
(1986)
Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens
Infect Control Hosp Epidemiol
Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983
Int J Syst Bacteriol
Stenotrophomonas maltophilia and Burkholderia cepacia
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
Clin Microbiol Rev
Fimbria and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces
Cell Microbiol
Infection due to Xanthomonas maltophilia in patients with haematologic malignancy
Rev Infect Dis
Stenotrophomonas maltophilia intestinal colonization in hospitalized oncology patients with diarrhea
Clin Infect Dis
Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients
Infect Control Hosp Epidemiol
Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and review of the literature
Rev Infect Dis
Novel nosocomial infections by Stenotrophomonas maltophilia: a reported case from Lucknow, North India
J Clin Microbiol
Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignanacies
Clin Infect Dis
Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: role of severe neutropenia and mucositis
Clin Infect Dis
Genomic diversity of the genus Stenotrophomonas
Int J Syst Bacteriol
Evidence of nosocomial Stenotrophomonas maltophilia cross-infection in a neonatology unit analyzed by three molecular typing methods
Infect Control Hosp Epidemiol
Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes
Clin Infect Dis
Nosocomial infection caused by Xanthomonas maltophilia. A case–control study of predisposing factors
Infect Control Hosp Epidemiol
Xanthomonas maltophilia bacteremia in immunocompromised haematological patients
Scand J Infect Dis
Cited by (120)
Appropriate antibiotic therapy is a predictor of outcome in patients with Stenotrophomonas maltophilia blood stream infection in the intensive care unit
2023, Journal of Microbiology, Immunology and InfectionRemoval of As(III) and Cr(VI) from aqueous solutions by Bixa orellana leaf biosorbent and As(III) removal using bacterial isolates from heavy metal contaminated site
2022, Journal of the Indian Chemical SocietyEmergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan
2022, Journal of Microbiology, Immunology and InfectionCitation Excerpt :Stenotrophomonas maltophilia, a non-fermenting gram-negative bacterium, is an important nosocomial pathogen in hospital settings.1